Tag : T-Cell

Latest News

Isolating Single T-cells of Interest using an Optofluidic Platform

Newsemia
Researchers are in desperate need of single-cell analysis techniques and those that allow the isolation of high-value T-cells for research and development. Source link...
Latest News

Universal 'One-Size-Fits-All' Cancer Treatment

Newsemia
Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers. Source link...
Latest News

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

Newsemia
The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies. Source link...
Biology

Modality Solutions Webinar Replay: Cold Chain Validation Best Practices Including CAR T-cell and ADC Immunotherapies

Newsemia
HOUSTON (PRWEB) November 22, 2019 Modality Solutions, biopharmaceutical cold chain engineering firm, hosted a live webinar covering a step-by-step cold chain validation guide to meet...
Biology

Immatics Implements Genedata Biologics® into Proprietary T-Cell Receptor Discovery and Engineering XCEPTOR® Platform

Newsemia
BASEL, Switzerland (PRWEB) November 12, 2019 Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies , a clinical-stage...
Neurology

Phase 2 clinical trial of CAR T-cell therapy starts at Atlantic Health System

Newsemia
Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of...
Latest News

Lupin partners with Abbvie to develop and commercialize new targeted oncology treatments

Newsemia
Pharma major Lupin Limited and global biopharmaceutical company AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1)...
Latest News

Antibody Screening Tools; Improving Workflows

Newsemia
Antibody screening tools have exponentially increased the rate that candidates can be screened, multiplexing will increase processing to thousands per hour.¬ Source link...
Gastroenterology

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Newsemia
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy